GW Pharma had a US$3 billion market cap prior to one dollar of revenue from epidiolex. I agree the value will come from the IP.
Any revenue in the next couple of years would be a small cherry on top of the value created by the clinical programs. And importantly the company now has a bullet proof balance sheet to execute, regardless of what global markets do.
- Forums
- ASX - By Stock
- IHL
- General discussion
General discussion, page-14680
-
-
- There are more pages in this discussion • 5,502 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
CC9
CHARIOT CORPORATION LTD
MD - Shanthar Pathmanathan, Geologist - David Trabert
MD - Shanthar Pathmanathan
Geologist - David Trabert
SPONSORED BY The Market Online